Researchers to test new treatment for AML

06/6/2010 | Gainesville Sun (Fla.), The

Researchers at the University of Florida Shands Cancer Center in Gainesville have received FDA approval for a Phase I trial of Oxi4503, an experimental treatment that damages leukemia cells and eliminates the blood vessels that allow the cells to thrive. The trial will involve patients with acute myelogenous leukemia who are no longer responding to standard treatments.

View Full Article in:

Gainesville Sun (Fla.), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel
Cardinal Health
Columbus, OH
Regulatory Affairs Specialist
Stryker
Mahwah, NJ
Sr. Principal OptoMechanical Engineer - 14000008M2
Abbott
San Jose, CA
Sr. Principal Electrical Engineer - 14000008LR
Abbott
San Jose, CA
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA